Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
about
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.The polypill approach - An innovative strategy to improve cardiovascular health in Europe.Improving cardiovascular protection: focus on a cardiovascular polypill.Role of the polypill for secondary prevention in ischaemic heart disease.Cost-effectiveness of adherence-enhancing interventions: a systematic review.Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.Polypills for the prevention of Cardiovascular diseases.The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges.Cholesterol-lowering drugs: science and marketing.Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study.
P2860
Q30235416-B55FA6D4-1403-49FD-8BFB-ACD20ACE501AQ30248710-F4174B79-91D6-41DB-9A15-14F74FBBAE58Q30398270-3FF4E287-14AB-4914-BD35-A50F36C6672CQ38664558-0C7E0D47-3947-42C8-9391-30AFD29B4601Q38670591-101C7EB9-C44A-4673-A391-B113D99D5255Q38687403-FC3061DD-5162-4464-8CD8-D58B32B97624Q38701607-0BBFAC90-03CE-4B56-AF6F-20FB209AF383Q38809466-EF528200-5609-4A2A-ACB9-57D8259DA40BQ39231217-830440DF-B37D-4746-BF51-633DE7E1A53AQ40427749-AE293A46-F8EA-4C63-BCAE-7B0E7B14D486Q41617873-ABDB61CB-88BE-4A4F-AD8E-AA2092924A1EQ47874524-69AE9FB9-1C18-4FA4-97AA-E0485D19BAF6Q51193262-7F43F5F2-3CF5-483C-A90E-E11E57C9E564Q51740192-30F6714E-8100-4274-85C9-8208108E38B4Q55289230-A22BC897-E538-4D84-8414-A52E72DED358
P2860
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness and public ...... nce using a polypill in the UK
@ast
Cost-effectiveness and public ...... nce using a polypill in the UK
@en
type
label
Cost-effectiveness and public ...... nce using a polypill in the UK
@ast
Cost-effectiveness and public ...... nce using a polypill in the UK
@en
prefLabel
Cost-effectiveness and public ...... nce using a polypill in the UK
@ast
Cost-effectiveness and public ...... nce using a polypill in the UK
@en
P2093
P2860
P1433
P1476
Cost-effectiveness and public ...... nce using a polypill in the UK
@en
P2093
Alfredo Gracia
Fernando García Alonso
Ginés Sanz
Kamal Desai
Ruth Chapman
Sarah Brand
Seye Abogunrin
P2860
P304
P356
10.1136/BMJOPEN-2014-007111
P577
2015-05-09T00:00:00Z